Methods for improving drug efficacy

1. A method for improving drug efficacy in a patient having an obstructive lung disease, comprising:

administering a therapeutically effective dose of an inhaled anticholinergic drug to the patient, wherein the inhaled anticholinergic drug has a reference efficacy when given as an initial bronchodilator, and a second reference efficacy when given as a second bronchodilator, wherein the patient has undergone, prior to the administration of the inhaled anticholinergic drug, a denervation procedure that includes injuring, either temporarily or permanently, a nerve trunk extending along a wall of an airway or a bronchial branch of the vagus nerve to modulate nerve activity in the autonomic nervous system of the patient by preventing acetylcholine from influencing postjunctional activities to reduce airway obstruction in at least one obstructed airway in a lung of the patient, and wherein a post-treatment efficacy of the inhaled anticholinergic drug following said denervation procedure is greater than the second reference efficacy of the inhaled anticholinergic drug when given as a second bronchodilator.

2. A method for treating a patient having an obstructive lung disease, comprising:

(a) performing a denervation procedure to modulate nerve activity in an autonomic nervous system of the patient by preventing acetylcholine from influencing postjunctional activities to reduce obstruction in a distal airway in a lung of the patient, wherein the denervation procedure includes injuring, either temporarily or permanently, a nerve trunk extending along a wall of an airway or a bronchial branch of the vagus nerve; and

(b) subsequently administering a therapeutically effective dose of an inhaled anticholinergic drug while the obstruction is reduced in the distal airway such that the inhaled anticholinergic drug is delivered to the distal airway,

wherein steps (a) and (b) have a treatment efficacy greater than a reference efficacy of the inhaled anticholinergic drug, wherein the reference efficacy of the inhaled anticholinergic drug is defined as an efficacy of the inhaled anticholinergic drug after the inhaled anticholinergic drug has been administered as a second bronchodilator after administration of a first bronchodilator.

3. The method of claim 2 , wherein step (a) is performed without causing permanent damage to non-nerve tissue.

4. The method of claim 2 , wherein step (a) comprises attenuating nerve activity in a portion of a parasympathetic nervous system of the patient.

5. The method of claim 2 , wherein step (a) also comprises stimulating nerve activity in a portion of a sympathetic nervous system of the patient.

6. The method of claim 2 , wherein step (a) comprises modulating nerve activity along a first airway of the patient, the at least one obstructed airway is a higher generation airway of the first airway, and the modulating nerve activity includes modulating activity in a nerve which carries signals to or from the higher generation airway.

7. The method of claim 2 , wherein step (a) comprises modulating nerve activity of a pulmonary plexus.

8. The method of claim 2 , wherein step (a) comprises modulating nerve activity of a bronchial branch of the vagus nerve.

9. The method of claim 2 , wherein step (a) comprises damaging a bronchial branch of the vagus nerve.

10. The method of claim 2 , wherein step (a) also comprises stimulating the portion of the parasympathetic nervous system with electrical impulses to block nervous system signals from traveling past the portion of the parasympathetic nervous system.

11. The method of claim 2 , wherein the at least one obstructed airway results from smooth muscle contraction, thickening of airway wall, mucous accumulation, or a combination thereof.

12. The method of claim 2 , wherein the patient suffers from chronic obstructive pulmonary disease (COPD).

13. The method of claim 2 , wherein the patient suffers from asthma.

14. The method of claim 2 , wherein the patient suffers from cystic fibrosis.

15. The method of claim 2 , further comprising administering the inhaled anticholinergic drug to the patient prior to step (a), wherein steps (a) and (b) have a treatment efficacy greater than an efficacy of the inhaled anticholinergic drug delivered prior to step (a).

16. The method of claim 2 , wherein the denervation procedure prevents the acetylcholine from influencing postjunctional activities by inhibiting release and/or production of acetylcholine.

17. The method of claim 2 , wherein step (a) comprises damaging a portion of the parasympathetic nervous system.

18. The method of claim 17 , wherein damaging the portion of the parasympathetic nervous system comprises applying energy to the portion of the parasympathetic nervous system.

19. The method of claim 18 , wherein applying energy to the portion of parasympathetic nervous system comprises applying thermal energy, microwave, electrical energy, cryogenic energy, acoustic energy, radio frequency energy, pulsed high voltage energy, mechanical energy, ionizing radiation, or optical energy to the portion of the parasympathetic nervous system.

20. The method of claim 18 , wherein applying energy to the portion of parasympathetic nervous system does not cause permanent damage to any interior airway walls of the patient.

21. The method of claim 18 , further comprising protecting an interior airway wall of the patient from permanent damage while applying the energy.

22. The method of claim 2 , wherein the nerve trunk is damaged by delivering energy from an interventional device.

23. The method of claim 22 , wherein the energy is delivered from within the airway.

24. The method of claim 22 , wherein the energy is delivered from outside the airway.

25. The method of claim 2 , wherein the denervation procedure prevents the acetylcholine from influencing postjunctional activities by inhibiting binding of acetylcholine to receptor sites in nerve cells.

26. The method of claim 25 , wherein the receptor sites comprise muscarinic (M) receptors.